Showing results (1-10 of 88) with videos related to
Sort By:
Pageof 9
Cancer Cell|November 15, 2022
Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?Kylee H Maclachlan, Alexander M LesokhinBest Practice & Research. Clinical Haematology|March 7, 2020
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of actionKitsada Wudhikarn, Beatriz Wills, Alexander M LesokhinBlood Cancer Discovery|October 12, 2023
An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple MyelomaRoss Firestone, Alexander M Lesokhin, Saad Z UsmaniOncoimmunology|March 26, 2013
Myeloid-derived suppressor sells and the efficacy of CD8<sup>+</sup> T-cell immunotherapyAlexander M Lesokhin, Taha Merghoub, Jedd D WolchokCancer Immunology Research|August 3, 2019
Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple MyelomaAlexander M Lesokhin, Susan Bal, Ashraf Z BadrosCurrent Opinion in Oncology|September 25, 2014
Harnessing the immune system for cancer therapyEric L Smith, Dmitriy Zamarin, Alexander M LesokhinCancer Journal (Sudbury, Mass.)|January 24, 2018
Clinical Development of PD-1 Blockade in Hematologic MalignanciesMatthew J Pianko, Aaron D Goldberg, Alexander M LesokhinJournal of Virology|July 23, 2002
Inhibition of chemokine expression by adenovirus early region three (E3) genesAlexander M Lesokhin, Fernando Delgado-Lopez, Marshall S HorwitzThe Journal of Experimental Medicine|September 28, 2011
Hiding the road signs that lead to tumor immunityDavid A Schaer, Alexander M Lesokhin, Jedd D WolchokClinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2017
Immunotherapy of Lymphoma and Myeloma: Facts and HopesMatthew J Pianko, Alison J Moskowitz, Alexander M LesokhinPageof 9